Brand Reference: Zyloprim
| Metric | Verified Benchmark | Source |
|---|---|---|
| Allopurinol RxNorm Concept ID | 519 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0380 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $24.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.10 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $6.20 / mo | 24 Zero-PHI Verified Patient Logs |
Oxypurinol metabolite non-competitively inhibits reduced xanthine oxidase, halting terminal purine oxidation of hypoxanthine/xanthine to uric acid while quenching xanthine-oxidase-generated endothelial superoxide anions.
Classified under Purine Analogue Xanthine Oxidase & Endothelial Superoxide Inhibitor (Rx), Allopurinol exhibits a $18.90/month gap between standard U.S. retail cash counters ($24.00) and verified direct-to-patient routing ($5.10) anchored to $0.0380 CMS unit cost.
Pharmacokinetic profiling of Allopurinol demonstrates an elimination half-life of 1.5 hours parent / 15–25 hours active oxypurinol with 80%–90% oral systemic bioavailability; clearance proceeds via aldehyde oxidase conversion to oxypurinol; renal glomerular clearance, reaching clinical onset within 2–3 weeks serum urate < 5.5 mg/dl.
Titration schedules for Allopurinol (100 mg PO daily starter → 200–300 mg PO once daily after meal) require excluding hla-b*5801 allele carriers (screen han chinese, korean, thai, or black patients prior to start for scar prevention); azathioprine/6-mp co-use without 75% dose cut; real-world patient logs highlight mobilization gout flare without colchicine bridge (18% of reports), maculopapular rash (4% of reports) alongside a 88.40% Worth-It consensus.
Across 24 verified cash-pay logs, Allopurinol achieves a 88.40% Worth-It rating with out-of-pocket spend averaging $6.20/mo versus $24.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 100 mg PO daily starter for Allopurinol; monthly out-of-pocket dropped to $4.50 compared with $24.00 retail.
Completed 10 weeks on Allopurinol (200–300 mg PO once daily after meal). Zero notable side effects on steady dosing.
Consistent biomarker response on 100 mg PO daily starter Allopurinol sourced via Cost Plus Drugs ($5.92/mo cash pay without insurance prior authorization).